Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease

Research output: Contribution to journalJournal articleResearchpeer-review

Background: Nonalcoholic fatty liver disease (NAFLD) is suggested as a risk factor for chronic kidney disease (CKD). The incidence of NAFLD is rising globally in parallel to the increasing incidences of obesity and type 2 diabetes. Diabetes remains the leading cause of CKD, but the co-existence of NAFLD, CKD, and type 2 diabetes is not well elucidated. Here, we evaluated the prevalence of NAFLD in patients with type 2 diabetes with and without CKD. Methods: This was a cross-sectional study including 50 patients with type 2 diabetes and CKD stages 3-5 (no dialysis), and 50 patients with type 2 diabetes without CKD. Liver fat content was estimated by proton magnetic resonance spectroscopy and magnetic resonance imaging proton density fat fraction. NAFLD was defined as liver fat fraction >= 5.6% according to guidelines. Results: Mean age was 72 +/- 4.9 years in patients with CKD and 65.9 +/- 7.8 years in patients without CKD (p < 0.0001). Three out of four participants were men. BMI was 28.6 +/- 3.5 kg/m(2) and 27 +/- 4.0 kg/m(2) in patients with and without CKD, respectively (p = 0.0087). NAFLD was identified in 22 (44%) patients with CKD and 19 (38%) patients without CKD (p = 0.6845). Median (IQR) liver fat fraction was 4.7% (3.0-8.5) and 4.1% (2.9-7.7) in patients with and without CKD, respectively (difference in geometric means 5.3%, 95% CI -23; 45, p = 0.7463). Conclusion: These findings do not support any association between NAFLD and CKD (stages 3-5) in patients with type 2 diabetes.

Original languageEnglish
JournalNephron
Volume147
Issue number6
Pages (from-to)317–328
ISSN1660-8151
DOIs
Publication statusPublished - 2023

    Research areas

  • Chronic kidney disease, Magnetic resonance imaging, Nonalcoholic fatty liver disease, Prevalence, Type 2 diabetes, GAMMA-GLUTAMYL-TRANSFERASE, HEPATIC STEATOSIS, PREVALENCE, RISK, ASSOCIATION, MELLITUS, EPIDEMIOLOGY, FIBROSIS

ID: 335674249